EUVIMEDEUVIMED entdecken
Vergleichsstudie

Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033

Gittan Blezer, Karl Patterson, Tomáš MIčoch, Jana Alahakoon, Yizhen Lai, Vivek Khurana, Raquel Aguiar-Ibáñez

Expert Review of Pharmacoeconomics & Outcomes Research · 16.03.2026 · 26 (3) · 429-441

DOI: 10.1080/14737167.2026.2634755 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026-03. Verfasst von Gittan Blezer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lumanity, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Immunotherapy, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyImmune Checkpoint InhibitorsNeoplasmsHumansCzech RepublicFemaleNeoplasm StagingMarkov ChainsQuality-Adjusted Life YearsEfficiencyCarcinoma, Renal CellMelanomaTriple Negative Breast NeoplasmsMiddle AgedDisease-Free SurvivalKidney NeoplasmsNeoplasm MetastasisB7-H1 AntigenProgrammed Cell Death 1 ReceptorAged

Stichwörter der Autor:innen

Anti-PD-(L)1Immune checkpoint inhibitorsearly-stage cancerlife-yearsmelanomapembrolizumabrenal cell carcinomatriple-negative breast cancer

Substanzen

Immune Checkpoint InhibitorsCD274 protein, humanB7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Lumanity, Utrecht, Netherlands.
  • Lumanity, Sheffield, UK.
  • MSD, Prague, Czech Republic.
  • Merck & Co. Inc., Rahway, NJ, USA.
  • Value & Implementation Outcomes Research, MSD Sharp & Dohme GmbH, Munich, Germany.
  • Merck Canada Inc., Kirkland, QC, Canada.

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Blezer, G., Patterson, K., MIčoch, T., Alahakoon, J., Lai, Y., Khurana, V., & Aguiar-Ibáñez, R. (2026). Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 429-441. https://doi.org/10.1080/14737167.2026.2634755

Vancouver

Blezer G, Patterson K, MIčoch T, Alahakoon J, Lai Y, Khurana V, et al. Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(3):429-441. doi:10.1080/14737167.2026.2634755

BibTeX
@article{Blezer2026,
  author = {Blezer, Gittan and Patterson, Karl and MIčoch, Tomáš and Alahakoon, Jana and Lai, Yizhen and Khurana, Vivek and Aguiar-Ibáñez, Raquel},
  title = {Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {3},
  pages = {429--441},
  doi = {10.1080/14737167.2026.2634755}
}
Kostenlos starten →